| Meet 2007's closers and closers in waiting
For the most part in fantasy baseball, when we talk about relief pitchers we're referring to closers. If you're in an 8-12 team league, closers usually comprise most of your relief pitching because they are the only ones who can get you saves on a regular basis. But in some leagues, middle relief guys can add some value, especially in head-to-head leagues where holds is a category or in Rotisserie leagues. Another way to add value to your pitching staff is to utilize relievers, often middle relievers, to maximize your ratios (ERA and WHIP), while adding solid strikeout numbers, not to mention adding the odd win. In some situations like the Twins, Yankees, Mets and Angels, the pitcher currently closing is pretty much locked into that position. Barring a catastrophicinjury or a Derrick Turnbow-like implosion, the setup man in "waiting" carries very little value.
Sweeten Up Your Meals With Floribbean Dishes, Featuring OsoSweet Onions
Acclaimed cookbook author Chef Aliza Green, whose latest effort is Starting with Ingredients: Quintessential Recipes for the way we Really Cook, has created a special menu of colorful Floribbean dishes that feature OsoSweet onions. Floribbean fare is a style of cooking that combines the best of Florida's traditions with Caribbean and Cuban flavors. (Photo: http://www.newscom.com/cgi-bin/prnh/20070124/AQW010) "One of the chief ingredients for Floribbean cuisine is onions," says Green, national spokesperson for OsoSweets. "In the winter months, this can be a challenge, since most sweet onions are Spring and Summer crops. Thankfully, OsoSweet onions, which are grown in Chile, are in season from January to March and are just the thing to bring a sweet-sharp flavor to these dishes." (RECIPES ATTACHED) Green's special menu features a variety of make-ahead dishes that the whole family can kick back and enjoy.
(AFX UK Focus) 2007-01-29 12:30 GMT: Schering-Plough 4Q profit up 75 percent
KENILWORTH, N.J. (AFX) - Drug maker Schering-Plough Corp. said Monday its fourth-quarter profit surged 75 percent as strong sales of its Remicade and Nasonex treatments helped offset rising costs. Net income after paying preferred dividends totaled $182 million, or 12 cents per share, up from $104 million, or 7 cents per share, a year ago. The latest quarter includes a charge of 4 cents per share to streamline the company's manufacturing operations and a charge of a penny per share to license an over-the-counter heartburn treatment. Excluding items, the company posted profit of 17 cents per share, in line with Wall Street's consensus estimate, according to a Thomson Financial poll. Sales grew 14 percent to $2.65 billion from $2.32 billion a year ago, beating analysts' forecast of $2.53 billion.
|
